13F Holdings
中文EN

BRTX BioRestorative Therapies, Inc.

Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1505497 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.5%
TTM net income YoY8.6%
TTM EPS YoY27.9%
Revenue 3-yr CAGR38.4%
Net income 3-yr CAGR—

Margins

Gross margin92.1%
Operating margin-3,975.0%
Net margin-3,089.6%
FCF margin—
EBITDA margin-3,916.2%

Returns

ROE-241.1%
ROA-147.7%
ROIC (approx.)-465.4%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets34.8%
Debt / equity0.00x
Current ratio2.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$359,700$401,000$145,800$119,800$46,000
Cost of revenue$23,844$28,072———
Gross profit$335,856$372,928$145,800——
R&D expense$10.09M$6.71M$4.03M$3.51M$729,058
SG&A expense$5.89M$5.22M$11.33M$15.58M$25.62M
Operating income-$15.65M-$11.56M-$15.22M-$18.97M-$26.31M
Pretax income-$14.20M-$8.98M———
Net income-$14.24M-$8.98M-$10.42M-$13.22M-$44.30M
EBITDA-$15.44M-$11.37M-$15.06M-$18.85M-$26.22M
EPS (basic)-1.58-1.16-2.47-3.65-37.30
EPS (diluted)-1.58-1.16-2.47-3.65-37.30
Weighted avg. shares (diluted)8.99M7.76M4.22M3.62M1.19M
Banking
Net interest income$266,207$616,077$552,293$11,650-$1.82M
Balance sheet
Cash & equivalents$1.51M$547,890$884,377$1.71M$21.03M
Short-term investments$1.44M$10.18M$10.18M$13.04M—
Receivables$15,500$188,400$19,300$16,000$5,000
Current assets$3.14M$11.14M$11.39M$15.13M$21.47M
PP&E, net$358,767$362,936$356,055$261,003$37,993
Intangibles$534,198$623,945$713,692$803,438$589,740
Total assets$4.08M$12.28M$12.61M$16.43M$22.45M
Current liabilities$3.72M$3.75M$2.61M$5.98M$363,822
Long-term debt————$250,000
Total debt————$250,000
Total liabilities$3.72M$3.75M$2.61M$6.14M$856,497
Shareholders' equity$356,744$8.53M$10.00M$10.29M$10.78M
Net debt————-$20.78M
Shares outstanding8.88M6.92M4.71M3.68M3.52M
Cash flow statement
Operating cash flow-$10.79M-$8.23M-$6.43M-$5.91M-$3.33M
Capital expenditure$116,069$106,189$171,043$265,223$30,658
Free cash flow-$10.91M-$8.34M-$6.60M-$6.18M-$3.36M
Investing cash flow$8.90M$514,529$3.25M-$13.40M-$30,658
Financing cash flow$2.85M$7.38M$2.35M—$21.32M
Depreciation & amortization$209,985$189,056$165,735$120,545$89,108
Stock-based compensation$3.33M$2.81M$7.78M$12.61M$23.11M
Share buybacks$0————

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.